$KIN (Kindred Biosciences, Inc.)

$KIN {{ '2016-08-23T11:52:15+0000' | timeago}} • Announcement

Biopharma company $KIN said it has submitted the Effectiveness Technical Section of the New Animal Drug Application for Mirataz ointment to the FDA for managing weight loss in cats. Company plans to submit the Safety Technical Section in 3Q16. Based on safety data review, the drug appears to be well tolerated.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$ZTS {{ '2017-11-07T19:49:47+0000' | timeago}} • Infographic

$ZTS Zoetis Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$PAHC {{ '2017-11-07T14:26:50+0000' | timeago}} • Announcement

$PAHC's BoD declared a quarterly cash dividend of $0.10 per share on its Class A and B common stock. The dividend is payable on Dec. 27, 2017 to stockholders of record as of Dec. 6, 2017.

$AGN {{ '2017-11-03T20:08:36+0000' | timeago}} • Announcement

$AGN, which was criticized by the Federal Court recently on its Restasis deal, narrowed its revenue outlook for FY17. Allergan also widened its GAAP loss from the previous estimate, reflecting the generics competition and the potential patent losses. With regards to the Federal Court's decision on Restasis drug, the company had filed an appeal.

$AGN {{ '2017-11-03T19:30:46+0000' | timeago}} • Announcement

Despite an increase in revenue, $AGN swung to a loss in 3Q17, hurt by impairment charges related to its Restasis drug and Teva stake holding. Net loss was $4.03Bil or $12.07 per share versus net income of $15.2Bil or $38.58 per share a year ago. Revenue rose 11% to $4.03Bil, helped by the sales growth in drugs like Botox and Juvederm collection.

$AGN {{ '2017-11-01T14:05:00+0000' | timeago}} • Infographic

$AGN Allergan Plc Earnings AlphaGraphic: Q3 2017 Highlights

$ISRG {{ '2017-10-23T16:52:19+0000' | timeago}} • Webcast

$ISRG upped its FY17 procedure growth guidance range to 15% to 16% from prior estimate of 14% to 15% above the 753,000 procedures performed in 2016. In regards to system placements, although the proportion of 3Q17 systems placed under operating leases was slightly lower than 2Q17, the company continues to expect an upward trend for FY17.

$ISRG {{ '2017-10-23T16:49:27+0000' | timeago}} • Webcast

$ISRG continues to launch its da Vinci X systems in new regions, as it launched in nine countries during 3Q17 and anticipates adding four more in 4Q17. The company said that da Vinci Xi makes up roughly 75% of new placements, da Vinci X makes up approx. 10% of new placements in its limited early launch and with the balance made up by Si technology.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

Recent Transcripts

ITCI (Intra-Cellular Therapies, Inc.)
Wednesday, November 8 2017 - 1:30pm
JAZZ (Jazz Pharmaceuticals Public Limited Company)
Tuesday, November 7 2017 - 9:30pm
KIN (Kindred Biosciences, Inc.)
Tuesday, November 7 2017 - 9:30pm
PAHC (Phibro Animal Health Corporation)
Tuesday, November 7 2017 - 2:00pm
INFI (Infinity Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 1:30pm
PETX (Aratana Therapeutics, Inc.)
Friday, November 3 2017 - 12:30pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
INSY (INSYS Therapeutics, Inc.)
Thursday, November 2 2017 - 12:30pm
NLNK (NewLink Genetics Corporation)
Thursday, November 2 2017 - 12:30pm
INSM (Insmed Incorporated)
Thursday, November 2 2017 - 12:30pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 12:30pm
NBIX (Neurocrine Biosciences Inc.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
ICPT (Intercept Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
NURO (NeuroMetrix Inc.)
Thursday, October 19 2017 - 12:00pm
PAHC (Phibro Animal Health Corporation)
Thursday, August 31 2017 - 1:00pm
JAZZ (Jazz Pharmaceuticals Public Limited Company)
Tuesday, August 8 2017 - 8:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm

AlphaGraphics you may like